Genus Past Earnings Performance

Past criteria checks 0/6

Genus's earnings have been declining at an average annual rate of -3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 6.6% per year. Genus's return on equity is 0.4%, and it has net margins of 1.2%.

Key information

-3.0%

Earnings growth rate

-3.3%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate6.6%
Return on equity0.4%
Net Margin1.2%
Next Earnings Update27 Feb 2025

Recent past performance updates

There May Be Some Bright Spots In Genus' (LON:GNS) Earnings

Oct 22
There May Be Some Bright Spots In Genus' (LON:GNS) Earnings

Recent updates

Lacklustre Performance Is Driving Genus plc's (LON:GNS) Low P/S

Nov 20
Lacklustre Performance Is Driving Genus plc's (LON:GNS) Low P/S

Genus (LON:GNS) Has Affirmed Its Dividend Of £0.217

Oct 23
Genus (LON:GNS) Has Affirmed Its Dividend Of £0.217

There May Be Some Bright Spots In Genus' (LON:GNS) Earnings

Oct 22
There May Be Some Bright Spots In Genus' (LON:GNS) Earnings

Genus plc Just Missed EPS By 72%: Here's What Analysts Think Will Happen Next

Sep 08
Genus plc Just Missed EPS By 72%: Here's What Analysts Think Will Happen Next

The Price Is Right For Genus plc (LON:GNS)

Jun 16
The Price Is Right For Genus plc (LON:GNS)

Estimating The Fair Value Of Genus plc (LON:GNS)

Apr 20
Estimating The Fair Value Of Genus plc (LON:GNS)

Is Genus (LON:GNS) Using Too Much Debt?

Mar 25
Is Genus (LON:GNS) Using Too Much Debt?

With A 26% Price Drop For Genus plc (LON:GNS) You'll Still Get What You Pay For

Mar 05
With A 26% Price Drop For Genus plc (LON:GNS) You'll Still Get What You Pay For

Genus (LON:GNS) Has Affirmed Its Dividend Of £0.103

Feb 25
Genus (LON:GNS) Has Affirmed Its Dividend Of £0.103

Getting In Cheap On Genus plc (LON:GNS) Might Be Difficult

Jan 17
Getting In Cheap On Genus plc (LON:GNS) Might Be Difficult

Does This Valuation Of Genus plc (LON:GNS) Imply Investors Are Overpaying?

Dec 10
Does This Valuation Of Genus plc (LON:GNS) Imply Investors Are Overpaying?

We Think Genus (LON:GNS) Is Taking Some Risk With Its Debt

Nov 03
We Think Genus (LON:GNS) Is Taking Some Risk With Its Debt

Calculating The Intrinsic Value Of Genus plc (LON:GNS)

Sep 09
Calculating The Intrinsic Value Of Genus plc (LON:GNS)

Is Genus (LON:GNS) A Risky Investment?

Mar 29
Is Genus (LON:GNS) A Risky Investment?

Is Genus (LON:GNS) Using Too Much Debt?

Dec 21
Is Genus (LON:GNS) Using Too Much Debt?

It's Unlikely That Shareholders Will Increase Genus plc's (LON:GNS) Compensation By Much This Year

Nov 17
It's Unlikely That Shareholders Will Increase Genus plc's (LON:GNS) Compensation By Much This Year

Genus (LON:GNS) Has Affirmed Its Dividend Of £0.217

Oct 25
Genus (LON:GNS) Has Affirmed Its Dividend Of £0.217

Genus (LON:GNS) Is Paying Out A Dividend Of £0.217

Oct 11
Genus (LON:GNS) Is Paying Out A Dividend Of £0.217

Genus' (LON:GNS) Dividend Will Be £0.217

Sep 11
Genus' (LON:GNS) Dividend Will Be £0.217

A Look At The Fair Value Of Genus plc (LON:GNS)

Sep 09
A Look At The Fair Value Of Genus plc (LON:GNS)

A Look At The Intrinsic Value Of Genus plc (LON:GNS)

May 31
A Look At The Intrinsic Value Of Genus plc (LON:GNS)

Is Genus (LON:GNS) A Risky Investment?

Mar 29
Is Genus (LON:GNS) A Risky Investment?

Genus (LON:GNS) Has Re-Affirmed Its Dividend Of UK£0.10

Feb 27
Genus (LON:GNS) Has Re-Affirmed Its Dividend Of UK£0.10

Is Genus plc (LON:GNS) Expensive For A Reason? A Look At Its Intrinsic Value

Jan 22
Is Genus plc (LON:GNS) Expensive For A Reason? A Look At Its Intrinsic Value

With EPS Growth And More, Genus (LON:GNS) Is Interesting

Oct 29
With EPS Growth And More, Genus (LON:GNS) Is Interesting

Here's Why Genus (LON:GNS) Can Manage Its Debt Responsibly

Oct 14
Here's Why Genus (LON:GNS) Can Manage Its Debt Responsibly

Genus (LON:GNS) Could Easily Take On More Debt

Apr 05
Genus (LON:GNS) Could Easily Take On More Debt

Is Genus' (LON:GNS) 235% Share Price Increase Well Justified?

Mar 18
Is Genus' (LON:GNS) 235% Share Price Increase Well Justified?

Trade Alert: The Independent Non-Executive Chairman Of Genus plc (LON:GNS), Iain G. Ferguson, Has Just Spent UK£73k Buying 150% More Shares

Feb 28
Trade Alert: The Independent Non-Executive Chairman Of Genus plc (LON:GNS), Iain G. Ferguson, Has Just Spent UK£73k Buying 150% More Shares

I Ran A Stock Scan For Earnings Growth And Genus (LON:GNS) Passed With Ease

Feb 26
I Ran A Stock Scan For Earnings Growth And Genus (LON:GNS) Passed With Ease

Revenue & Expenses Breakdown

How Genus makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:GNS Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24669811673
31 Mar 246712111475
31 Dec 236733310193
30 Sep 236813310093
30 Jun 236903311077
31 Mar 236763410075
31 Dec 22662349073
30 Sep 22628388973
30 Jun 22593418973
31 Mar 22582399271
31 Dec 21570379568
30 Sep 21572429668
30 Jun 21574479768
31 Mar 21570459370
31 Dec 20566428971
30 Sep 20559398971
30 Jun 20551358871
31 Mar 20536378066
31 Dec 19520397261
30 Sep 19504237261
30 Jun 1948987261
31 Mar 1948017656
31 Dec 18471-78151
30 Sep 18470188151
30 Jun 18470438251
31 Mar 18473558048
31 Dec 17476677945
30 Sep 17467507945
30 Jun 17459337845
31 Mar 17441407540
31 Dec 16422477134
30 Sep 16405487134
30 Jun 16388497134
31 Mar 16388406832
31 Dec 15388316429
30 Sep 15393356429
30 Jun 15399406429
31 Mar 15394366028
31 Dec 14389325628
30 Sep 14381305728
30 Jun 14372295828
31 Mar 14366275928
31 Dec 13360256028

Quality Earnings: GNS has a large one-off loss of £47.8M impacting its last 12 months of financial results to 30th June, 2024.

Growing Profit Margin: GNS's current net profit margins (1.2%) are lower than last year (4.8%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: GNS's earnings have declined by 3% per year over the past 5 years.

Accelerating Growth: GNS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: GNS had negative earnings growth (-76.3%) over the past year, making it difficult to compare to the Biotechs industry average (-18.2%).


Return on Equity

High ROE: GNS's Return on Equity (0.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:10
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genus plc is covered by 18 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert ChantryBerenberg
Francesco GregoriCharles Stanley Securities
Benjamin MooreGoldman Sachs